Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Results from a phase 3 clinical trial of Pfizer’s Lyme disease vaccine candidate found it was more than 70 percent effective at preventing the illness. Participants in Pfizer’s trial received four ...

Babies whose mothers were vaccinated against respiratory syncytial virus earlier in pregnancy had stronger protection against ...

Shares of Moderna (MRNA), Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt future mRNA vaccine development under the ...

Dublin, April 07, 2026 (GLOBE NEWSWIRE)-- The "Messenger RNA Market - A Global and Regional Analysis: Application and Regional Analysis - Analysis and Forecast, 2025-2035" has been added to ...

Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above The investigational vaccine candidate was well tolerated ...

Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease cases compared to the placebo arm (95% CI 15.8, 93.5) Efficacy of 74.8% from 1-day post-dose 4 ...

CAPE CANAVERAL, Fla. -- NASA's Apollo moonshots are a tough act to follow, even after all this time. As four astronauts get set to blast off on humanity's first trip to the moon in more than half a ...